Van Berkom & Associates Inc. Sells 346,150 Shares of RadNet, Inc. $RDNT

Van Berkom & Associates Inc. trimmed its stake in shares of RadNet, Inc. (NASDAQ:RDNT) by 29.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 846,918 shares of the medical research company’s stock after selling 346,150 shares during the period. RadNet comprises about 2.1% of Van Berkom & Associates Inc.’s portfolio, making the stock its 28th largest position. Van Berkom & Associates Inc.’s holdings in RadNet were worth $58,387,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. AlphaCore Capital LLC acquired a new position in RadNet in the 3rd quarter worth $851,000. Commonwealth Equity Services LLC bought a new position in RadNet during the 3rd quarter worth about $271,000. Mirae Asset Global Investments Co. Ltd. bought a new position in RadNet during the 3rd quarter worth about $343,000. Vise Technologies Inc. acquired a new stake in shares of RadNet in the 3rd quarter valued at about $325,000. Finally, Modera Wealth Management LLC acquired a new stake in shares of RadNet in the 3rd quarter valued at about $207,000. 77.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on RDNT shares. Truist Financial boosted their price target on RadNet from $90.00 to $94.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of RadNet in a research report on Tuesday, September 22nd. Jefferies Financial Group reiterated a “buy” rating on shares of RadNet in a report on Friday, July 31st. Zacks Research raised RadNet from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 9th. Finally, Barclays lifted their target price on RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a research report on Friday, August 28th. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $90.00.

Key Stories Impacting RadNet

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet reported Q3 EPS of $0.30, beating the $0.22 consensus estimate by 35%. Revenue rose 22.1% year over year to $638.26 million, while the company also reported record quarterly revenue and adjusted EBITDA. RadNet Q3 financial results and revised guidance
• Positive Sentiment: The company raised its 2026 revenue guidance to $2.5 billion–$2.6 billion, versus analyst expectations of about $2.5 billion. This marked its third consecutive quarterly guidance increase. RadNet Q3 earnings and guidance
• Negative Sentiment: Revenue of $638.26 million narrowly missed the $639.97 million consensus estimate, tempering an otherwise strong quarter. RadNet earnings report

RadNet Stock Performance

Shares of RDNT stock opened at $78.38 on Tuesday. RadNet, Inc. has a 12 month low of $50.82 and a 12 month high of $85.84. The company’s fifty day simple moving average is $72.64 and its 200-day simple moving average is $65.43. The firm has a market cap of $6.17 billion, a PE ratio of -290.29 and a beta of 1.42. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.94.

RadNet (NASDAQ:RDNT) last released its earnings results on Sunday, November 8th. The medical research company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.08. The business had revenue of $638.26 million during the quarter, compared to the consensus estimate of $639.97 million. RadNet had a negative net margin of 0.93% and a positive return on equity of 2.61%. The firm’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.20 earnings per share. Equities research analysts expect that RadNet, Inc. will post 0.49 EPS for the current fiscal year.

RadNet Company Profile

RadNet, Inc operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging.

The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.

RadNet also develops digital health and artificial intelligence solutions through its subsidiary DeepHealth, including technology intended to support imaging workflows and assist with image analysis.